Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2023-06-09 Director's Dealing
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-06-09 English
Director's Dealing 2023
Director's Dealing
2023-06-09 English
Director's Dealing 2023
Director's Dealing
2023-06-09 English
Director's Dealing 2023
Director's Dealing
2023-06-09 English
Director's Dealing 2023
Director's Dealing
2023-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the submission of matters to a vote of security holders at the 2023 Annual Meeting, detailing voting results on director elections and ratification of the auditor. It also includes an amendment to the Non-Employee Director Compensation Program approved by the Board. The document is not a full annual or quarterly report, nor is it a proxy statement or earnings release. It primarily reports voting results and a board-approved compensation amendment. According to the filing definitions, official results from shareholder votes at any general meeting fall under Declaration of Voting Results & Voting Rights Announcements (DVA). The amendment to the compensation program is described but not detailed as a full remuneration report, so it does not qualify as DEF 14A. Therefore, the best classification is DVA.
2023-06-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.